FDA Grants Breakthrough Therapy Designation To Biogen's Salanersen In Treating Muscular Atrophy

Biogen's investigational candidate salanersen received FDA Breakthrough Therapy Designation for spinal muscular atrophy, a meaningful regulatory step that can accelerate development and review. The news is favorable for Biogen's pipeline and highlights potential future value in its SMA program, though it remains early-stage and not an approval.

Analysis

Biogen's investigational candidate salanersen received FDA Breakthrough Therapy Designation for spinal muscular atrophy, a meaningful regulatory step that can accelerate development and review. The news is favorable for Biogen's pipeline and highlights potential future value in its SMA program, though it remains early-stage and not an approval.